Description
Surgical Site Infections (SSIs) are the third-most commonly reported nosocomial infection accounting for 10 to 40% of all nosocomial infections, leading to a 5-fold increase in hospital readmissions. SSI incidence rates are also an important outcome measure of the quality of surgical care. Re-evaluating antibiotic protocols, including prophylactic strategies, is crucial to enhance outcomes and curb antimicrobial resistance. A promising option is Ceftriaxone + B-lactamase inhibitor for SSI prevention.